Tuberculosis is an epidemic requiring new molecules with high potency and minimum side
effects for its treatment. In the same respect, this review emphasises on important target enoyl-acyl
carrier protein reductase or INHA crucial in the completion of the FAS II cycle. INHA has retained
its fame since the inception of the drug Isoniazid, as inhibitors have a long residence time hence good
activity. One of the causes of the failure of conventional drugs is resistance towards activating or target
genes. Here, we propose direct inhibitors that do not need prior activation by Kat G. Some of the
categories are Aryl amide, Piperazine, Thiadiazole, Benzamide, etc., that are specifically active
against INHA, along with their structure-activity relationship. Many of them are efficient in micromolar
concentration, whereas Pyrazole carboxamide is active in nanomolar concentration and derivative
of 4-hydroxy pyridones was effective in vivo. Natural products are also in the way to combat tuberculosis.
Furthermore, from available proteins of wild and mutant strains, new leads can be designed successfully
by utilizing information of co-crystallized ligands.